NKGen Biotech Announces Upcoming Presentation on Autologous NK Cell Therapy at the 5th International Cell & Gene Therapy China Summit & Exhibition

May 16, 2024

https://www.globenewswire.com/news-release/2024/05/16/2883377/0/en/NKGen-Biotech-Announces-Upcoming-Presentation-on-Autologous-NK-Cell-Therapy-at-the-5th-International-Cell-Gene-Therapy-China-Summit-Exhibition.html

SANTA ANA, Calif., May 16, 2024 (GLOBE NEWSWIRE) — NKGen Biotech, Inc. (Nasdaq:NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic and CAR-NK natural killer (“NK”) cell therapeutics, today announced that Paul Y. Song, MD, Chairman and Chief Executive Officer of NKGen, will present highlights of the Company’s cryopreserved, autologous, non-genetically modified NK cell therapy product, SNK01, which has demonstrated enhanced cytotoxicity and activating receptor expression for the treatment of neurodegenerative diseases and solid tumors, at the 5th International Cell & Gene Therapy China Summit & Exhibition (CGCS) to be held in Nanjing, China, from May 22–24, 2024.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.